Valbiotis SA

EPA:ALVAL.PA

1.33 (EUR) • At close September 18, 2024
Bedrijfsnaam Valbiotis SA
Symbool ALVAL.PA
Munteenheid EUR
Prijs 1.332
Beurswaarde 21,017,962
Dividendpercentage 0%
52-weken bereik 1.07 - 7.5
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sebastien Peltier HDR, Ph.D.
Website https://www.valbiotis.com

An error occurred while fetching data.

Over Valbiotis SA

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and

Vergelijkbare Aandelen

Poxel S.A. logo

Poxel S.A.

POXEL.PA

0.53 EUR

ABIONYX Pharma SA logo

ABIONYX Pharma SA

ABNX.PA

1.25 EUR

Crossject Société Anonyme logo

Crossject Société Anonyme

ALCJ.PA

2.375 EUR

Visiomed Group SA logo

Visiomed Group SA

ALVMG.PA

0.173 EUR

GeNeuro SA logo

GeNeuro SA

GNRO.PA

0.065 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)